EPZM News and Press, Epizyme Inc. From 01/06/20

Epizyme ( EPZM -6.5% ) has exercised its option to sell $50M more of its common stock to Royalty Pharma under its funding agreements announced in November 2019 under which the latter initially bought $100M of stock. More news on: Epizyme, Inc., Healthcare stocks news, Stocks on the m...

Additional Capital Further Extends Company’s Operating Runway into 2022 Commercially Prepared to Launch Tazemetostat for Epithelioid Sarcoma; PDUFA Date Set for January 23, 2020 Epizyme, Inc . (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenet...

Fresh off today's positive advisory committee vote backing tazemetostat for epithelioid sarcoma, Epizyme (NASDAQ: EPZM ) files another marketing application with the FDA for the EZH2 inhibitor. More news on: Epizyme, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Submission Marks On-time Execution of Second NDA Submission for Tazemetostat in 2019 Epizyme, Inc . (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Dru...

Epizyme, Inc . (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) voted 11 - 0 in favor of the benefit-risk profile of tazemetostat as ...

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, announced today that trading of its common stock has been halted. The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) is meeting at 8:00 a.m...

Noteworthy events during the week of December 15 - 21 for healthcare investors. More news on: Avadel Pharmaceuticals plc, AstraZeneca PLC, Merck & Co., Inc., Healthcare stocks news, Read more ...

In 1992, Congress passed the Prescription Drug User Fee Act (PDUFA) allowing the U.S. Food and Drug Administration (FDA) to collect fees from drug manufacturers to fund the drug review and approval process. To promote getting novel medicines to patients expeditiously, the act requires the FDA to...

Introduction Through Week 49, the Premium Portfolio has gained +27.75%, beating the S&P 500 benchmark, while actively trading in 14 fewer weeks according to the Momentum Gauge timing signals. These returns represent better than 3 times the return of the Barclay Hedge Fund Index average r...

December 9, 2019 Palm Beach, FL –December 9, 2019 – One of the latest market reports in the published by Credence Research, Inc. shows that the Multiple Myeloma Treatment market, which was valued at USD $8,398.3 Mn in 2016, is expected to reach USD $21,221.8 Mn ...